ABSTRACT
NTP TR 352 NIH 89-2807 SEP 89 UNDER THE CONDITIONS OF THESE 2-YEAR AQUEOUS GAVAGE STUDIES, THERE WAS NO EVIDENCE OF CARCINOGENIC ACTIVITY OF N-METHYLOLACRYLAMIDE FOR MALE OR FEMALE F344/N RATS RECEIVING DOSES OF 6 OR 12 MG/KG PER DAY. THERE WAS CLEAR EVIDENCE OF CARCINOGENIC ACTIVITY OF N-METHYLOLACRYLAMIDE FOR MALE B6C3F1 MICE, BASED ON INCREASED INCIDENCES OF NEOPLASMS OF THE HARDERIAN GLAND, LIVER, AND LUNG. THERE WAS CLEAR EVIDENCE OF CARCINOGENIC ACTIVITYOFN-METHYLOLACRYLAMIDEFORFEMALEB6C3F1MICE, BASED ON INCREASED INCIDENCES OF NEOPLASMS OF THE HARDERIAN GLAND, LIVER, LUNG, AND OVARY. PAPER, TEXTILES/ADHESIVES, BINDERS, SURFACE COATINGS, VARNISH RESINS, LATEX FILMS, SIZING AGENTS AND FINISHED COTTON
872-50-4 CHEM NAME : *** N-METHYLPYRROUDONE (NMP) REPORT 01
REPORT02
EPA 8EHQ-l087-0695 NOV 87 UNDER CONDITIONS OF TERATOLOGY STUDY, CPD ADMINISTERED IP TO PREGNANT NMRI MICE AT 610 AND 1525 MM3/KG OR ORALLY AT 1026AND2565 MM3/KG ON THE llTHTHRU 15TH DAY OF GESTATION, INCREASED RESORPTION RATE,# OF RUNTS, REDUCTIONS IN WEIGHTS AND LENGTHS OF FETUSES. ALSO INCREASE IN RATE OF BIRTH DEFECTS. CPD ADMINISTERED ORALLY AT 320 OR 970 MM3/ KG TO PREGNANT SPRAGUE-DAWLEY RATS ON DAYS 6 THRU 15 OF GESTATION. HIGH DOSE PRODUCED 95% EMBRYOLETHALITY AND DEFORMITIES IN 8115 OF SURVIVING FETUSES.
